{
  "id": "kawasaki-disease",
  "title": "Kawasaki disease",
  "lang": "en",
  "source_lang": "en",
  "summary": "Kawasaki disease is an acute childhood vasculitis that can damage coronary arteries and cause lasting cardiovascular complications.",
  "category": "health",
  "subcategory": "diseases",
  "type": "concept",
  "aliases": [
    "Mucocutaneous lymph node syndrome",
    "Kawasaki syndrome"
  ],
  "generated_at": "2026-11-02",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/kawasaki-disease/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/kawasaki-disease/",
      "json": "https://aiwiki.page/zh/kawasaki-disease.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Kawasaki disease is an acute, systemic vasculitis that predominantly affects children younger than five years. It causes prolonged fever and characteristic changes involving the eyes, mouth, skin, extremities, and cervical lymph nodes. Its most important complication is injury to the coronary arteries, which supply the heart muscle. Coronary artery dilatation and aneurysm formation can lead to clotting, narrowing of the vessel, and myocardial ischemia, sometimes years after the initial illness.\n\nThe cause remains unknown. Epidemiological and laboratory findings support an abnormal immune response to one or more environmental triggers in genetically susceptible children, but no single infectious agent or exposure has been established as the cause. Diagnosis rests on clinical findings supported by laboratory testing and cardiac imaging; there is no definitive diagnostic blood test. Treatment with intravenous immunoglobulin substantially reduces coronary complications, while the extent of coronary involvement determines subsequent monitoring and antithrombotic treatment."
    },
    {
      "heading": "Recognition and development of the disease concept",
      "text": "The Japanese pediatrician Tomisaku Kawasaki recognized the characteristic illness in a child examined in 1961. In 1967, he published a Japanese-language report describing 50 children with an acute febrile syndrome involving the skin, mucous membranes, and lymph nodes. An English-language report in 1974 helped establish international recognition. The descriptive name mucocutaneous lymph node syndrome reflected the most conspicuous clinical features before the cardiovascular consequences were fully understood.\n\nEarly descriptions emphasized an apparently self-limited illness. Subsequent investigation of sudden deaths and pathological specimens demonstrated coronary arteritis, aneurysms, and coronary thrombosis. These findings changed the disease concept from a febrile mucocutaneous syndrome to a systemic vascular disorder with potentially persistent cardiac consequences. The introduction of two-dimensional echocardiography made it possible to identify coronary abnormalities noninvasively in living children rather than principally through angiography or autopsy.\n\nRecognition outside Japan showed that Kawasaki disease was not confined to a particular country or ancestry. Historical descriptions suggest that compatible illnesses may have occurred before the syndrome received its present name, but retrospective identification is limited by incomplete clinical records and the absence of modern imaging. Its recognition in the twentieth century does not establish when the disease first arose.\n\nTreatment developed through a combination of Japanese clinical experience and controlled international studies. Aspirin was used for its anti-inflammatory and antiplatelet effects. During the 1980s, studies established that intravenous immunoglobulin reduced coronary artery abnormalities when administered during the acute illness. A pivotal 1986 multicenter randomized controlled trial demonstrated the benefit of adding intravenous immunoglobulin to aspirin; later trials supported a single high-dose infusion rather than a divided multiday regimen.\n\nKawasaki disease subsequently became recognized as a major cause of acquired heart disease in children in high-income countries. Its importance differs from that of many childhood febrile illnesses: the outward symptoms usually resolve, but arterial damage may persist. Modern disease classification therefore distinguishes the acute inflammatory episode from the long-term coronary condition that can remain after recovery."
    },
    {
      "heading": "Epidemiology and population patterns",
      "text": "Kawasaki disease occurs worldwide, but its incidence varies substantially by geography and ancestry. Japan has the highest extensively documented national rates, exceeding 300 cases per 100,000 children younger than five years annually in some recent pre-pandemic surveys. Rates in South Korea and Taiwan are also high. In the continental United States, commonly reported estimates are roughly 15–25 cases per 100,000 children younger than five years annually, although estimates depend on the period, population, and method of case identification.\n\nApproximately four-fifths of affected children are younger than five years. The peak age is in infancy and early childhood, and boys are affected about one and a half times as often as girls. Disease in adolescents and adults is uncommon but documented. Very young infants are a particularly important subgroup because they may show fewer of the characteristic external findings while remaining at substantial risk of coronary injury.\n\nAncestry-related differences persist outside East Asia. Children of Japanese ancestry in Hawaii, for example, have higher incidence than children from several other ancestry groups living in the same setting. This observation, together with familial clustering, supports a contribution from inherited susceptibility. Siblings of affected children have a higher risk than the general population, and disease has been reported across generations. Nevertheless, most cases occur without a known family history, and Kawasaki disease is not inherited as a simple single-gene disorder.\n\nSeasonality varies geographically. Winter and spring peaks are common in temperate Northern Hemisphere populations, although other patterns occur. Large Japanese epidemics were recorded in 1979, 1982, and 1986. Temporal clustering, geographical variation, and seasonal fluctuations have encouraged investigation of infectious and environmental triggers. These patterns do not, by themselves, identify a particular cause or establish person-to-person transmission.\n\nRecurrence is uncommon but well established, occurring in a few percent of children in some cohorts. Reported recurrence rates vary with population and follow-up duration. A previous episode therefore does not provide complete protection against another episode.\n\nComparisons between countries require caution. Hospital discharge databases, national physician surveys, and active public health surveillance capture cases differently. Access to pediatric cardiology and recognition of incomplete presentations also affect recorded incidence. During the COVID-19 pandemic, several regions reported decreases in conventional Kawasaki disease alongside the emergence of a distinct postinfectious inflammatory syndrome. Changes in social contact, environmental exposures, healthcare use, and diagnostic classification complicate interpretation of these observations."
    },
    {
      "heading": "Susceptibility, immune activation, and vascular injury",
      "text": "No single cause of Kawasaki disease has been established. The leading explanatory model involves an environmental trigger acting on a susceptible host, followed by a dysregulated immune response. The age distribution suggests that developmental changes in immunity or patterns of exposure matter. Seasonal clustering and occasional epidemics are compatible with an infectious contribution, but extensive investigation has not identified one pathogen that accounts for the disease consistently.\n\nGenetic association studies have implicated several immune-regulatory pathways. Variants near or within ITPKC, FCGR2A, BLK, CD40, and CASP3 have been associated with susceptibility or disease-related outcomes in particular populations. ITPKC participates in intracellular calcium signaling and regulation of lymphocyte activation; FCGR2A encodes a receptor involved in responses to antibody-containing immune complexes. These associations identify biological pathways rather than a single diagnostic gene, and their effects vary between populations.\n\nThe acute illness involves activation of innate and adaptive immunity. Neutrophils, monocytes, macrophages, and lymphocytes participate in the inflammatory response, while elevated cytokines include interleukin-1, interleukin-6, and tumor necrosis factor. Endothelial activation, recruitment of inflammatory cells, and degradation of structural proteins can weaken the arterial wall. Kawasaki disease is therefore immune-mediated, but it is not established as a conventional autoimmune disease directed against one defined self-antigen.\n\nPathological studies describe overlapping processes rather than one uniform lesion. Acute necrotizing arteritis can damage the arterial wall during the first weeks of illness. Subacute or chronic vasculitis may continue for longer. A further process, luminal myofibroblastic proliferation, involves accumulation of myofibroblast-like cells and extracellular material within the vessel, contributing to progressive narrowing. The balance between wall destruction, repair, and luminal proliferation influences later coronary anatomy.\n\nAlthough the disease is classified predominantly as a medium-vessel vasculitis, inflammation can affect vessels and tissues beyond the coronary arteries. The heart muscle, pericardium, and valves may be involved, and systemic inflammation explains many noncardiac manifestations. The special clinical importance of the coronary arteries reflects their susceptibility to aneurysm formation and the consequences of interrupted blood supply to the myocardium.\n\nSeveral causal hypotheses remain under investigation, including conventional infectious triggers, toxin-mediated immune activation, and inhaled environmental agents. Associations with atmospheric conditions or airborne transport have generated testable hypotheses, but no particular windborne substance has been established as the cause. Similarly, detection of a respiratory or other pathogen in an affected child neither explains Kawasaki disease generally nor necessarily excludes its diagnosis."
    },
    {
      "heading": "Clinical manifestations and course",
      "text": "The illness typically begins with persistent fever and marked irritability. Without effective treatment, fever commonly lasts one to two weeks and may persist longer. The principal clinical findings are bilateral nonpurulent conjunctival injection, oral and lip changes, a polymorphous rash, changes in the hands and feet, and cervical lymphadenopathy. These findings frequently appear sequentially, so their absence during one examination does not establish that they were absent throughout the illness.\n\nEye redness generally affects both bulbar conjunctivae without purulent discharge. Oral changes include red or fissured lips, diffuse redness of the mouth and pharynx, and a “strawberry tongue” with prominent papillae. Discrete oral ulcers, marked exudative pharyngitis, and purulent conjunctivitis are less characteristic and raise consideration of other diagnoses. The rash can be maculopapular, scarlatiniform, or otherwise variable; no single rash morphology defines the disease.\n\nDuring the acute phase, the palms and soles may become red, and the hands and feet can develop firm edema. Peeling around the fingernails and toenails commonly appears during the following two to three weeks, when fever and some other signs may already have subsided. Cervical lymphadenopathy is often unilateral, with at least one enlarged lymph node measuring 1.5 cm or more in its greatest dimension. It is the least consistently present of the five principal features.\n\nOther manifestations reflect widespread inflammation. Children may have vomiting, diarrhea, abdominal pain, hepatitis, gallbladder hydrops, arthritis, or sterile pyuria. Aseptic meningeal inflammation can contribute to irritability. Redness or induration at a previous bacillus Calmette–Guérin vaccination site is a recognized finding, particularly in younger children in countries where this vaccine is routinely used. None of these additional findings is independently diagnostic.\n\nThe conventional clinical course is divided into acute, subacute, and convalescent phases. The acute febrile phase usually occupies the first one to two weeks. The subacute phase includes periungual peeling, a rise in platelet count, and the period during which coronary aneurysms may become apparent or enlarge. In convalescence, clinical findings resolve and inflammatory markers return toward normal, often over six to eight weeks. These intervals overlap and are modified by treatment.\n\nSome children present with cardiovascular instability, termed Kawasaki disease shock syndrome. Others develop severe inflammatory complications, including macrophage activation syndrome. Infants may present primarily with unexplained prolonged fever, whereas older children occasionally have prominent neck swelling or abdominal findings that initially dominate the clinical picture. The intensity of visible mucocutaneous changes does not reliably measure the severity of coronary involvement."
    },
    {
      "heading": "Clinical diagnosis and differential diagnosis",
      "text": "Kawasaki disease is a clinical diagnosis supported by laboratory and imaging findings. The classic diagnostic framework consists of fever lasting at least five days together with at least four of the five principal clinical features: bilateral nonexudative conjunctival injection, oral changes, polymorphous rash, extremity changes, and cervical lymphadenopathy. Experienced clinicians can establish the diagnosis earlier in a sufficiently characteristic presentation; the five-day threshold is not an absolute biological boundary.\n\nIncomplete Kawasaki disease refers to illness in which fewer principal clinical features are present but the overall evidence supports the diagnosis. It is not synonymous with mild disease. Incomplete presentations are especially important in infants, including those with prolonged unexplained fever and few external signs. Diagnostic algorithms combine the duration of fever, clinical findings, inflammatory markers, supplementary laboratory abnormalities, and echocardiographic findings.\n\nLaboratory testing usually demonstrates systemic inflammation. C-reactive protein and the erythrocyte sedimentation rate are commonly elevated. The complete blood count may show neutrophilic leukocytosis, anemia, and, particularly after the first week, thrombocytosis. Low albumin, increased alanine aminotransferase, and white blood cells in urine without a conventional bacterial urinary infection provide additional support. Platelet counts may be normal early; thrombocytopenia can occur in severe illness and does not exclude the diagnosis.\n\nNo laboratory pattern is specific enough to replace clinical assessment. A positive viral test can represent a concurrent infection, and neither respiratory symptoms nor detection of a virus automatically rules out Kawasaki disease. Conversely, fever, rash, and elevated inflammatory markers alone are insufficient to establish it. A normal early echocardiogram also does not exclude the disease because coronary changes can develop later.\n\nImportant alternative diagnoses include adenoviral infection, measles, scarlet fever, bacterial cervical lymphadenitis, toxic shock syndrome, and drug hypersensitivity reactions. Systemic juvenile idiopathic arthritis and other inflammatory disorders can also overlap. Features such as prominent exudative conjunctivitis, vesicular lesions, or a convincing alternative microbiological diagnosis help shape the differential, but interpretation depends on the complete clinical picture and its evolution.\n\nMultisystem inflammatory syndrome in children associated with SARS-CoV-2 is a particularly important overlapping condition. It generally affects older children than conventional Kawasaki disease and more often features prominent gastrointestinal symptoms, shock, myocardial dysfunction, lymphopenia, and thrombocytopenia. Kawasaki-like mucocutaneous findings can occur in both. The temporal relationship to COVID-19, laboratory pattern, age, and organ involvement contribute to distinguishing them; the syndromes are not treated as interchangeable diagnoses.\n\nDiagnostic uncertainty is greatest when findings are incomplete, appear at different times, or coexist with another illness. Documentation of earlier symptoms and repeated clinical assessment therefore play an important role in how the diagnosis is established."
    },
    {
      "heading": "Cardiac imaging and classification of coronary involvement",
      "text": "Echocardiography is the principal cardiac imaging technique during acute Kawasaki disease. It evaluates coronary artery dimensions, ventricular function, valve regurgitation, and pericardial fluid without ionizing radiation. Coronary assessment usually emphasizes the proximal right coronary artery, left main coronary artery, and left anterior descending artery, although visualization of more distal segments can be important. Image quality depends on patient size, cooperation, equipment, and operator experience.\n\nAbsolute coronary diameter is interpreted in relation to body size using a z score. In general statistical terms,\n\n\\[z=\\frac{x-\\mu}{\\sigma},\\]\n\nwhere \\(x\\) is the measured value, \\(\\mu\\) is the expected value for the reference population, and \\(\\sigma\\) is the corresponding standard deviation. In coronary practice, validated models relate expected dimensions and variability to body surface area. Different models can yield somewhat different results, particularly near classification thresholds, so consistent methodology matters.\n\nA widely used American Heart Association classification describes no involvement as a z score below 2 and dilatation only as a z score from 2 to below 2.5. Small aneurysms have z scores from 2.5 to below 5. Medium aneurysms have z scores from 5 to below 10 with an absolute diameter below 8 mm. Large or giant aneurysms have a z score of at least 10 or an absolute diameter of at least 8 mm. These categories connect anatomy to follow-up and thrombosis risk rather than simply describing appearance.\n\nSerial imaging is necessary because coronary abnormalities can evolve after the first examination. In uncomplicated cases, commonly used schedules include imaging at diagnosis, again within approximately one to two weeks, and around four to six weeks after treatment. Established or evolving abnormalities lead to more frequent and individualized assessment. A child whose arteries initially appear normal can subsequently develop enlargement, while an aneurysm may decrease in diameter during follow-up.\n\nOther imaging methods address questions that echocardiography cannot resolve adequately. Coronary computed tomography angiography provides detailed anatomy, including distal vessels, thrombus, calcification, and stenosis, but involves radiation and iodinated contrast. Cardiac magnetic resonance imaging can assess ventricular function, myocardial scar, and perfusion without ionizing radiation. Invasive coronary angiography remains important in selected complex cases and when an intervention is being considered.\n\nElectrocardiography and cardiac biomarkers complement imaging when myocardial involvement or ischemia is suspected. Neither a normal electrocardiogram nor resolution of fever establishes that the coronary arteries are unaffected. Long-term classification incorporates both the greatest documented coronary involvement and the current anatomy, because normalization of lumen diameter does not necessarily mean restoration of a normal arterial wall."
    },
    {
      "heading": "Initial anti-inflammatory and antiplatelet treatment",
      "text": "The central acute treatment is intravenous immunoglobulin, generally administered as a single total dose of 2 g/kg. It is usually given within the first ten days of illness once the diagnosis is established. Treatment after that interval is also used when fever, ongoing inflammation, or coronary abnormalities indicate continuing disease activity. Clinical protocols distinguish timely recognition from waiting for every classical feature to appear.\n\nIntravenous immunoglobulin has multiple immunomodulatory actions. Proposed mechanisms include altered Fc receptor signaling, modulation of cytokine activity, neutralization of inflammatory mediators, and effects on immune-cell activation. No single mechanism fully explains its effectiveness. Historical untreated cohorts had coronary aneurysm rates of approximately 20–25%; prompt immunoglobulin-based treatment reduces this to roughly 3–5%, although estimates vary with patient risk and the definition of coronary abnormality.\n\nAspirin is conventionally administered alongside immunoglobulin. During the febrile phase, protocols have used moderate doses of 30–50 mg/kg/day or higher doses of 80–100 mg/kg/day, usually divided. Once fever has resolved, treatment commonly changes to an antiplatelet dose of 3–5 mg/kg/day. Higher acute aspirin doses have not been shown convincingly to improve coronary outcomes compared with lower anti-inflammatory regimens, and practice differs between countries and centers.\n\nThe rationale for low-dose aspirin differs from that of acute anti-inflammatory treatment. By inhibiting platelet thromboxane production, aspirin reduces platelet aggregation during a period characterized by thrombocytosis and potentially abnormal coronary flow. In children without coronary abnormalities, antiplatelet treatment is commonly discontinued after follow-up confirms recovery, often around six to eight weeks. Persistent aneurysms lead to a different, risk-based antithrombotic strategy.\n\nSelected children at high risk of coronary complications receive additional anti-inflammatory treatment from the outset. Corticosteroids, generally as a defined course rather than an isolated dose, have improved coronary outcomes in some high-risk populations. In the Japanese RAISE trial, published in 2012, adding prednisolone to immunoglobulin reduced coronary abnormalities among children selected using a Japanese risk score. Risk scores developed in Japan have performed less well in several other populations, limiting direct transfer of their thresholds.\n\nTreatment also has implications for other aspects of care. Immunoglobulin can interfere with the immune response to certain live vaccines; United States guidance generally uses an 11-month interval after the Kawasaki disease dose before measles- or varicella-containing vaccination, subject to specific exceptions. Adverse effects of immunoglobulin include infusion reactions and, less commonly, hemolysis or aseptic meningitis. These considerations are distinct from the ongoing assessment of whether inflammation and coronary injury have been controlled."
    },
    {
      "heading": "Persistent inflammation and severe complications",
      "text": "Approximately 10–20% of children have persistent or recurrent fever after initial immunoglobulin treatment, with the proportion varying by population and definition. A commonly used definition of immunoglobulin resistance is fever that persists or recurs at least 36 hours after completion of the infusion, within the relevant acute illness period. Fever in this setting requires interpretation because intercurrent infection and other causes can coexist with Kawasaki disease.\n\nImmunoglobulin-resistant disease is associated with a higher risk of coronary abnormalities. Treatment options include another immunoglobulin infusion, corticosteroids, and targeted immunomodulatory agents. The choice depends on previous treatment, coronary findings, illness severity, and the clinical protocol. These approaches do not have identical evidence for every outcome, particularly the prevention of uncommon severe coronary events.\n\nInfliximab, a monoclonal antibody against tumor necrosis factor, has been studied for persistent disease. In the KIDCARE randomized trial, published in 2021, infliximab produced better fever-related outcomes and shorter hospitalization than a second immunoglobulin infusion, with less hemolytic anemia. The study did not establish superiority for prevention of coronary aneurysms. This distinction illustrates why rapid fever resolution cannot automatically be treated as equivalent to improved long-term coronary outcome.\n\nCyclosporine inhibits calcineurin-dependent signaling and has been investigated both in high-risk initial treatment and in refractory illness. Anakinra, which blocks the interleukin-1 receptor, has also been studied in resistant or severe cases. Their use reflects growing understanding of inflammatory pathways, but the evidence base and regulatory status differ between agents and jurisdictions. No one additional drug is uniformly preferred for every resistant presentation.\n\nSevere cardiovascular involvement can include myocardial dysfunction, valve regurgitation, pericardial effusion, and shock. In Kawasaki disease shock syndrome, impaired cardiac performance, vasodilatation, and increased vascular permeability may contribute simultaneously. This presentation can resemble sepsis or toxic shock syndrome and often requires intensive monitoring and organ support in addition to treatment of the inflammatory disease.\n\nMacrophage activation syndrome is an uncommon hyperinflammatory complication. Its features can include persistent fever, cytopenias, liver dysfunction, coagulopathy, and very high ferritin concentrations. These findings differ from the usual later thrombocytosis of uncomplicated Kawasaki disease. Recognition depends on the overall pattern rather than ferritin alone.\n\nAcute coronary thrombosis is a separate emergency, particularly in giant aneurysms. It can cause myocardial infarction even in a young child. Management may involve anticoagulation, thrombolysis, catheter-based procedures, or cardiac surgery, according to the coronary anatomy and clinical circumstances. Small children may not describe typical chest pain, making changes in cardiac function, electrocardiographic findings, and other signs especially important."
    },
    {
      "heading": "Long-term coronary outcomes and adult disease",
      "text": "Most children recover without persistent coronary abnormalities, especially after timely treatment. For those who develop aneurysms, long-term outcome depends strongly on the maximum aneurysm size, the number and location of affected segments, and whether thrombosis or stenosis develops. Small aneurysms are much more likely than giant aneurysms to return to a normal internal diameter.\n\nApparent regression does not necessarily restore normal vessel structure. A smaller lumen can result partly from remodeling and thickening of the arterial wall rather than complete healing. Persistent abnormalities may include altered elasticity, endothelial dysfunction, intimal proliferation, and later calcification. These processes help explain why a previously enlarged artery can remain clinically relevant after its diameter decreases.\n\nGiant aneurysms carry the greatest enduring risks. Blood flow within a large aneurysmal segment can become sluggish or disturbed, favoring clot formation. Narrowing can develop at the entrance or exit of an aneurysm or within remodeled segments, reducing blood supply to the heart muscle. Myocardial infarction can result from acute thrombosis, progressive stenosis, or a combination of mechanisms. Rupture is rare and is chiefly a concern in severe acute disease rather than the usual late complication.\n\nLong-term antithrombotic treatment is therefore stratified by coronary risk. Persistent small aneurysms generally involve antiplatelet therapy, whereas large or giant aneurysms commonly lead to combined antiplatelet and anticoagulant treatment. Warfarin and low-molecular-weight heparin have established roles in this setting. Bleeding risk, changing body size, interactions, and the practical demands of monitoring influence the treatment framework.\n\nFollow-up may include echocardiography, anatomical coronary imaging, and assessment for inducible myocardial ischemia. Significant obstructive disease can require catheter intervention or coronary artery bypass surgery. Procedures must account for unusual coronary anatomy, aneurysmal segments, calcification, and the patient's age; disease following Kawasaki vasculitis is not anatomically identical to ordinary adult atherosclerosis.\n\nTransition from pediatric to adult care is particularly important for people with persistent aneurysms or previous major coronary abnormalities. Their records include the greatest documented coronary dimensions, prior thrombosis, imaging findings, and interventions. Some adults first come to attention with coronary calcification, aneurysms, or myocardial infarction after an unrecognized childhood illness, although attributing such findings to Kawasaki disease requires consideration of other causes.\n\nFor individuals whose coronary arteries remain normal throughout the illness, available evidence is generally reassuring. Whether subtle vascular changes in this group translate into a meaningful increase in cardiovascular events decades later remains incompletely resolved. Long-term research is complicated by changing diagnostic criteria, improved treatment, and the relatively small number of people followed from early childhood into later adult life."
    }
  ],
  "links": [
    "vasculitis",
    "fever",
    "aneurysm",
    "thrombosis",
    "japan",
    "aspirin",
    "randomized-controlled-trial",
    "incidence",
    "united-states",
    "public-health-surveillance",
    "pandemic",
    "immune-system",
    "gene",
    "cytokine",
    "autoimmune-disease",
    "conjunctivitis",
    "rash",
    "edema",
    "lymph-node",
    "diarrhea",
    "abdominal-pain",
    "inflammation",
    "complete-blood-count",
    "measles",
    "covid-19",
    "x-ray-computed-tomography",
    "magnetic-resonance-imaging",
    "corticosteroid",
    "monoclonal-antibody",
    "sepsis",
    "thrombolysis",
    "warfarin",
    "surgery",
    "atherosclerosis"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}